Neoadjuvant camrelizumab plus chemotherapy versus chemotherapy alone for resectable esophageal squamous cell carcinoma: A Prospective Multicenter randomised controlled study
Background: Camrelizumab combined with chemotherapy has a very ideal therapeutic effect and low toxicity in the treatment of solid tumors. Camrelizumab plays an important role in the treatment of locally advanced esophageal squamouscell carcinoma. Methods: This study is a prospective, multicenter, randomised controlled study. Inclusion criteria were patients aged 18-75 years who had not received other treatments previously and had histologically confirmed resectable locally advanced esophageal squamous cell carcinoma (clinical stages cT1-4N1-3M0 and cT3-4N0M0). Random 1:1, patients received camrelizumab combined with chemotherapy (experimental group) or chemotherapy alone (control group). Results: From January 2021 to December 2024, 248 patients from four centers were enrolled. In the experimental group and the control group, 3 patients and 21 patients respectively did not receive surgical treatment. The surgical approach mainly involved endoscopic surgery. The R0 resection rate in the experimental group was 98.3%, the pathological complete response (pCR) rate was 20.7%, and the major pathological response (MPR) rate was 31.4%. In the control group, the R0 resection rate was 97.1%, the pCR rate was 11.5%, and the MPR rate was 20.2%. The median Event-free survival (EFS) was 32 months VS 20 months. Overall, the adverse reactions were mainly of grade 1-2. The incidence of grade 3 or higher adverse events was low in both groups (0.8% in the experimental group vs. 2.4% in the control group), and no grade 4 adverse events occurred in the experimental group. Conclusions: Research data shows that camrelizumab combined with chemotherapy has a definite efficacy and controllable safety in the neoadjuvant treatment of esophageal squamous cell carcinoma. Follow-up will be conducted to analyze the research data results and their correlation with the efficacy. Trial registration: Chinese Clinical Trial Registry (ChiCTR) ChiCTR2000040330. Registered on November 28, 2020. https://www.chictr.org.cn/showproj.html?proj=64767 This study adheres to the CONSORT 2025 guidelines for reporting randomized controlled trials.